European Union — European Medicines Agency & Eli Lilly and Company
3 shared events · Importance 3 · Last updated Jun 26, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
European Union — European Medicines Agency: Estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings on semaglutide product information in 2025. Its action sets a precedent that US regulators have not followed.
Eli Lilly and Company: Co-defendant in the NAION litigation involving Mounjaro, Zepbound and Trulicity. It says patient safety is its top priority and that it monitors safety reports, but the lawsuits create legal and reputational exposure for its GLP-1 portfolio.
Sep 21, 2026 · 20 articles
Domestic
European Union — European Medicines Agency: The European Union — European Medicines Agency recently recommended approval of Novo Nordisk's Semaglutide pill, which could pave the way for the first oral weight-loss drug in Europe, complementing France's reimbursement initiative.
Eli Lilly and Company: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.
May 28, 2026 · 6 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted designations to MiNK Therapeutics' Fabry gene therapy program.
Eli Lilly and Company: Eli Lilly and Company has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how European Union — European Medicines Agency and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard